Alex Spyropoulos, MD
Hematology & Oncology · Rochester, NYNPI 1073622874
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $536,136 of the $632,907 with a category attached, or 84.7%. 20 manufacturers reported payments, led by Janssen Research & Development, LLC at 24.4% of the total. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $2541.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$154K
- Janssen Scientific Affairs, LLC$136K
- Johnson & Johnson$99K
- AstraZeneca$84K
- Daiichi Sankyo Inc.$35K
- Grifols Shared Services North America, Inc.$21K
- plus $103K from 14 others
Across 22 payments — averaging $52,360 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.1M
- Grifols Therapeutics LLC$47K
- Boehringer Ingelheim$3K
What the payments were for
- Consulting fees$536,13685%
- Speaking & faculty fees$60,24310%
- Travel & lodging$31,0325%
- Food & beverage$5,4961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 36 | $154,280 |
| Janssen Scientific Affairs, LLC | 28 | $136,310 |
| Johnson & Johnson | 55 | $99,136 |
| AstraZeneca(2 entities) | 40 | $84,124 |
| Daiichi Sankyo Inc. | 26 | $35,394 |
| Grifols Shared Services North America, Inc. | 11 | $21,030 |
| Sanofi-aventis U.S. LLC | 6 | $14,891 |
| Bayer | 4 | $13,918 |
| E.r. Squibb & Sons, L.L.C. | 3 | $12,720 |
| Janssen Global Services, LLC | 11 | $12,075 |
| Novartis | 8 | $10,632 |
| Boehringer Ingelheim | 7 | $10,060 |
| BTG International Inc. | 4 | $9,904 |
| Diagnostica Stago, Inc | 2 | $4,000 |
| Roche Diagnostics International Ltd | 1 | $3,990 |
| CSL Behring | 1 | $3,056 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,622 |
| Siemens Medical Solutions USA, Inc. | 1 | $2,250 |
| Portola Pharmaceuticals, LLC | 3 | $1,865 |
| Arbor Pharmaceuticals, Inc. | 1 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$388,146
- Savaysa$27,810
- Thrombate III$20,875
- LOVENOX$14,828
- ANDEXXA$10,179
- PRAXBIND$9,069
- cobas 6800 System$3,990
- Kcentra$3,056
- PRADAXA$992
- NOT Specifically Atributed$650
How this compares
$632,907 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 63 | $98,386 |
| EliquisApixaban | 19 | $29,804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $99,136 | $98,38663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Rochester
- Adrienne VictorRochester$143K
- Brea LipeRochester$129K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.